ICU Medical, Inc. (FRA:IC7)
Germany · Delayed Price · Currency is EUR | Market Cap | 3.91B +44.7% |
| Revenue (ttm) | 1.89B -9.0% |
| Net Income | 26.34M |
| EPS | 1.05 |
| Shares Out | n/a |
| PE Ratio | 148.28 |
| Forward PE | 20.23 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 155.00 |
| Previous Close | 155.00 |
| Day's Range | 153.00 - 156.00 |
| 52-Week Range | 97.00 - 161.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About ICU Medical
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinf... [Read more]
News
ICU Medical price target raised to $200 from $180 at Raymond James
Raymond James raised the firm’s price target on ICU Medical (ICUI) to $200 from $180 and keeps a Strong Buy rating on the shares.
ICU Medical price target raised to $187 from $165 at Needham
Needham analyst Mike Matson raised the firm’s price target on ICU Medical (ICUI) to $187 from $165 and keeps a Buy rating on the shares. The firm cites higher earnings…
ICU Medical price target raised to $200 from $170 at BTIG
BTIG raised the firm’s price target on ICU Medical (ICUI) to $200 from $170 and keeps a Buy rating on the shares. ICU Medical delivered a strong Q2 with revenue,…
ICU Medical reports Q2 adjusted EPS $2.37, consensus $1.91
Reports Q2 revenue $551.68M, consensus $534.21M. Vivek Jain, ICU Medical’s (ICUI) Chief Executive Officer, said, “Second quarter results were ahead of our expectations for Infusion Systems and general...
ICU Medical raises FY26 adjusted EPS view to $9.60-$8.90 from $7.75-$8.45
Consensus $8.16. Raises FY26 adjusted EBITDA view to $415M-$435M from $400M-$430M. The company said, “For Fiscal Year 2026 the Company is updating its estimates of GAAP net income from a…
ICU Medical Earnings Call Transcript: Q2 2026
Q2 saw 6% organic revenue growth, record sales in consumables and infusion systems, and improved margins. Guidance for full-year adjusted EBITDA and EPS was raised, with strong free cash flow supporting debt reduction and a focus on margin expansion despite ongoing currency and tariff headwinds.
ICU Medical Earnings release: Q2 2026
ICU Medical released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
ICU Medical Slides: Q2 2026
ICU Medical has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
ICU Medical Quarterly report: Q2 2026
ICU Medical has published its Q2 2026 quarterly earnings report on August 6, 2026.
ICU Medical Announces Second Quarter 2026 Results and Updates its Fiscal Year 2026 Guidance
SAN CLEMENTE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial res...
ICU Medical Announces Time of Second Quarter 2026 Earnings Conference Call
SAN CLEMENTE, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of ...
Otsuka ICU Medical LLC Announces Over $500M Expansion of IV Solutions Manufacturing in North America
This expansion of IV solutions manufacturing will help enhance supply-chain resiliency, support portfolio development and advance non-DEHP innovation for the North American IV solutions market. Joint ...
ICU Medical initiated with a Buy at BTIG
BTIG initiated coverage of ICU Medical (ICUI) with a Buy rating and $170 price target ICU is a “pure-play infusion therapy company operating in one of healthcare’s most structurally defensive…
ICU Medical upgraded to Buy from Hold at Needham
Needham upgraded ICU Medical (ICUI) to Buy from Hold with a $165 price target The firm expects the company to benefit from an IV system replacement cycle as well as…
ICU Medical Transcript: AGM 2026
The meeting saw the election of all director nominees, approval of auditor ratification, executive compensation, and key governance amendments, including a 25% threshold for special meetings. A shareholder proposal for a 10% threshold was not approved.
ICU Medical reports Q1 adjusted EPS $1.72, consensus $1.75
Reports Q1 revenue $530.23M, consensus $531.12M. Vivek Jain, ICU Medical’s (ICUI) Chief Executive Officer, said, “First quarter results were generally in line with our expectations.”
ICU Medical Earnings Call Transcript: Q1 2026
Q1 2026 saw 1% organic revenue growth, record IV Systems sales, and 41% gross margin. Adjusted EPS rose 15% to $1.97, and guidance for the year remains unchanged despite oil and tariff headwinds. Integration costs are declining, and innovation continues in core businesses.
ICU Medical Earnings release: Q1 2026
ICU Medical released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
ICU Medical Quarterly report: Q1 2026
ICU Medical has published its Q1 2026 quarterly earnings report on May 7, 2026.
ICU Medical Slides: Q1 2026
ICU Medical has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
ICU Medical Announces First Quarter 2026 Results
SAN CLEMENTE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial resu...
ICU Medical price target lowered to $164 from $180 at KeyBanc
KeyBanc lowered the firm’s price target on ICU Medical (ICUI) to $164 from $180 to reflect lower peer multiples, while keeping an Overweight rating on the shares. The firm believes…
ICU Medical Announces Time of First Quarter 2026 Earnings Conference Call
SAN CLEMENTE, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of...
ICU Medical price target lowered to $163 from $178 at Piper Sandler
Piper Sandler analyst Jason Bednar lowered the firm’s price target on ICU Medical (ICUI) to $163 from $178 and keeps an Overweight rating on the shares. In addition to updated…
ICU Medical Transcript: 25th Annual Needham Virtual Healthcare Conference
The company has evolved into a global pure-play infusion leader, leveraging innovation and market consolidation for growth. Consumables and infusion systems segments are driving reliable earnings, with new products and software enhancing value. Margin expansion, tariff refunds, and share repurchases are key financial priorities.